The pharmacokinetics of pergolide in Parkinsonʼs disease
- 1 December 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 16, S9-S12
- https://doi.org/10.1097/00019052-200312001-00003
Abstract
Three decades of research have led to a fuller understanding of the pharmacokinetics of pergolide. Pergolide is rapidly absorbed following oral dosing, reaching peak plasma concentrations within 2-3 h. It is about 90% protein bound yet has negligible drug interactions. Pergolide undergoes extensive first-pass metabolism and is completely eliminated within 4-5 days. The metabolism/elimination profile varies between patients but is consistent within the individual, highlighting the importance of careful titration to an effective dose. Pergolide has a long half-life of about 21 h; this has interesting implications, as it should produce a more physiological or continuous stimulation of dopamine receptors, avoiding or delaying the induction of dyskinesia.Keywords
This publication has 6 references indexed in Scilit:
- Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposureMovement Disorders, 2003
- L -Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observationsPsychopharmacology, 2001
- Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate modelMovement Disorders, 2000
- Sensitive, Specific Radioimmunoassay for Quantifying Pergolide in PlasmaClinical Chemistry, 1992
- Physiologic disposition of pergolideClinical Pharmacology & Therapeutics, 1981